Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 30 March 2007:
Vol. 315. no. 5820, p. 1778
DOI: 10.1126/science.315.5820.1778
Prev | Table of Contents | Next

News of the Week

CLINICAL RESEARCH:
Testing a Novel Strategy Against Parkinson's Disease

Jennifer Couzin

One of the largest clinical trials ever for Parkinson's disease, announced last week by the National Institute of Neurological Disorders and Stroke, is experimental in more ways than one, officials say. Both its approach and the method of selecting the test agent, a supposed energy booster called creatine, are unorthodox. (Read more.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Neuroprotective Effect of Protein Kinase C{delta} Inhibitor Rottlerin in Cell Culture and Animal Models of Parkinson's Disease.
D. Zhang, V. Anantharam, A. Kanthasamy, and A. G. Kanthasamy (2007)
J. Pharmacol. Exp. Ther. 322, 913-922
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)